Astrazeneca's breast cancer drug fails late-stage trial
AstraZeneca LSE:AZN said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.